Drug Trial Radar · NCT06681766
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Dec 6, 2024
Primary completion
Apr 27, 2025
Study completion Apr 27, 2025
Sponsor
- Lead sponsor
- Larimar Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).
Conditions
- Friedreich Ataxia
Interventions
NomlabofuspDrug
Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
PlaceboDrug
The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of AEs, TEAEs, related TEAEs, Grade 3/4 TEAEs, and SAEsTime frame: Up to 72 days (including screening)
- Number of subjects with ISRsTime frame: Up to 37 days
- Change from baseline in electrocardiogram (ECG) parameter - heart rate (HR)Time frame: Baseline, Day 7
- Change from baseline in electrocardiogram (ECG) parameter - PR intervalTime frame: Baseline, Day 7
- Change from baseline in electrocardiogram (ECG) parameter - QRS complexTime frame: Baseline, Day 7
- Change from baseline in electrocardiogram (ECG) parameter - QT intervalTime frame: Baseline, Day 7
- Change from baseline in electrocardiogram (ECG) parameter - QTcF (Corrected QT Interval)Time frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - ejection fraction (EF)Time frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-diastolic volume (LV EDV)Time frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-systolic volume (LV ESV)Time frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - relative wall thickness (RWT)Time frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - left ventricular mass (LVM)Time frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - left ventricular posterior wall thicknessTime frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - septal wall thicknessTime frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - mitral valve inflow DopplerTime frame: Baseline, Day 7
- Change from baseline in echocardiogram (ECHO) parameter - tissue DopplerTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - sodiumTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - potassiumTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - glucoseTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - blood urea nitrogenTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - creatinineTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - calcium, chlorideTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - phosphorusTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - total proteinTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - total CO2Time frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - albuminTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - ASTTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - ALTTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - GGTTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - ALPTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - total bilirubinTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - uric acidTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - HbA1cTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - hemoglobinTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - hematocritTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - RBC countTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - RDWTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - MCVTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - MCHTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - platelet countTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - WBC countTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - ANCTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - EosinophilsTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - MonocytesTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - BasophilsTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - LymphocytesTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - BandsTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - NeutrophilsTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - CholesterolTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - HDL cholesterolTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - LDL cholesterolTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - TriglyceridesTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - very low-density lipoprotein cholesterolTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - pHTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - proteinTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - bloodTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - ketonesTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - bilirubinTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - urobilinogenTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - nitritesTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - leukocyte esteraseTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - colorTime frame: Baseline, Day 7
- Change from baseline in clinical laboratory assessment - specific gravityTime frame: Baseline, Day 7
- Change from baseline in pulse rateTime frame: Baseline, Day 7
- Number of subjects with abnormal physical examinationsTime frame: Up to 72 days (including screening)
- Number of subjects with suicidal ideation, suicidal behavior, and suicidal ideation or behavior based on the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 72 days (including screening)
- Number of subjects who discontinue treatment and/or studyTime frame: Up to 37 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Uncommon Cures
Chevy Chase, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.